Skip to main content
Caplight Logo









FoRx Therapeutics

FoRx Therapeutics

Private
BaselHealthcare & Life Scienceshttps://www.forxtherapeutics.com/

Last Round

Series A

Dec 18, 2025

Total Funding Raised

$60.85M

Company Overview

FoRx Therapeutics is a biotechnology company that develops a new generation of first-in-class oral small molecule cancer drugs focusing on novel DNA Replication Stress pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small molecule therapeuticsoncologyDNA damage responseDDRDNA replication stressDRSPARG inhibitorprecision medicinedrug discoverysolid tumorsbiotechclinical stage biotechcancer therapydrug developmenttargeted therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FoRx Therapeutics Comparables

Compare FoRx Therapeutics with similar companies based on industry and business-model similarity.

FoRx Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
858 Therapeutics
88%
Eisbach Bio GmbH
82%
Nodus Oncology
81%

FoRx Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 18, 2025
SeedApr 22, 2020

FoRx Therapeutics Investors

Notable investors and investment history

FoRx Therapeutics investors
InvestorRounds
Omega FundsSeed
EQT Life SciencesSeed, Series A
M VenturesSeries A, Seed
Pfizer VenturesSeed, Series A
PfizerSeed, Series A
Pfizer VenturesSeed, Series A
M VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 26, 2026

    FORX-428 shows potential for best-in-class PARG inhibition.

  • Mar 26, 2026

    Presented preclinical data for FORX-428 at ACS Spring 2026.

FoRx Therapeutics Filings

Explore SEC and related filing metadata, where available.

FoRx Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FoRx Therapeutics's valuation, stock price, and market status.

Is FoRx Therapeutics a public or private company?

FoRx Therapeutics is a private company.

What is the current stock price of FoRx Therapeutics?

FoRx Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is FoRx Therapeutics worth (valuation)?

Valuation information for FoRx Therapeutics is not publicly available.

Can I buy FoRx Therapeutics stock?

FoRx Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was FoRx Therapeutics's last funding round?

FoRx Therapeutics's most recent funding round was Series A on December 18, 2025.

Who are the main investors in FoRx Therapeutics?

Key investors in FoRx Therapeutics include Omega Funds, M Ventures.

Will FoRx Therapeutics IPO soon?

No public IPO plans have been announced for FoRx Therapeutics.

How can I track FoRx Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor FoRx Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBasel
Employee Range19
Year Founded2019
Last FundingDec 18, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?